Alendronate sodium
Catalog No.
A8359
Osteoclast-mediated bone resorption inhibitor
Featured Products
Alendronate sodium (CAS 129318-43-0) is a small molecule inhibitor of osteoclast-driven bone resorption. It acts by selectively inhibiting farnesyl diphosphate synthase (FPPS), an essential enzyme within the mevalonate (HMG-CoA reductase) pathway, exhibiting an IC50 of approximately 460 nM against recombinant human FPPS. Inhibition of FPPS prevents protein prenylation and sterol biosynthesis within osteoclasts, subsequently inducing apoptosis in macrophage-lineage cells. Alendronate sodium is commonly utilized in biomedical research focused on bone metabolism disorders, osteoclast biology, and evaluation of therapeutic strategies targeting bone density loss.
| Physical Appearance | A solid |
| Storage | Desiccate at -20°C |
| M.Wt | 271.08 |
| Cas No. | 129318-43-0 |
| Formula | C4H12NNaO7P2 |
| Synonyms | Fosamax |
| Solubility | insoluble in DMSO; insoluble in EtOH; ≥15 mg/mL in H2O with gentle warming |
| Chemical Name | sodium;(4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate |
| SDF | Download SDF |
| Canonical SMILES | C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.[Na+] |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
